{
    "clinical_study": {
        "@rank": "58562", 
        "arm_group": [
            {
                "arm_group_label": "Age Groups 1 and 2", 
                "arm_group_type": "Experimental", 
                "description": "Posaconazole oral suspension 12 mg/kg/day divided into 2 (BID) or 18 mg/kg/day divided into 2 (BID) or 3 (TID) doses for up to 28 days:\nAge Group 1:  Participants aged 2 to <7 years\nAge Group 2:  Participants aged 7 to <18 years"
            }, 
            {
                "arm_group_label": "Age Group 3", 
                "arm_group_type": "Experimental", 
                "description": "Posaconazole oral suspension 12 mg/kg/day or 18 mg/kg/day divided into 3 (TID) doses for up to 28 days:\nAge Group 3:  Participants aged 3 months to <2 years"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this dose-escalation study is to evaluate the pharmacokinetics, safety, and\n      tolerability of oral posaconazole in immunocompromised children with neutropenia or expected\n      neutropenia."
        }, 
        "brief_title": "A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Fungal Infections", 
        "condition_browse": {
            "mesh_term": "Mycoses"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented or anticipated neutropenia expected to last at least 7 days and only in\n             the following clinical situations: acute leukemia; myelodysplasia; severe aplastic\n             anemia; autologous hematopoietic stem cell transplantation (HSCT) recipients; high\n             risk neuroblastoma; advanced stage non-Hodgkin's lymphoma; recipients of allogeneic\n             HSCT during the pre-engraftment (neutropenia) period\n\n          -  Participants of child-bearing potential must use a medically accepted method of\n\n        contraception throughout the study and for at least 30 days after stopping study\n        medication, unless they are surgically or medically sterile or agree to remain abstinent.\n\n        Exclusion Criteria:\n\n          -  Proven invasive fungal infection (IFI) before study entry\n\n          -  Severe nausea and/or vomiting at screening\n\n          -  Received posaconazole within 10 days before screening\n\n          -  Unable to receive study drug by mouth or via an intestinal (enteral) tube\n\n          -  Females who are pregnant, intend to become pregnant during the study, or are\n             breastfeeding\n\n          -  History of anaphylaxis attributed to the azole class of antifungal agents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "3 Months"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01716234", 
            "org_study_id": "P03579", 
            "secondary_id": [
                "2007-004645-15", 
                "MK-5592-032"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "Age Groups 1 and 2", 
                "Age Group 3"
            ], 
            "description": "Posaconazole administered orally in 2 or 3 divided doses to participants stratified by age group", 
            "intervention_name": "Posaconazole oral suspension", 
            "intervention_type": "Drug", 
            "other_name": [
                "SCH 056592", 
                "MK-5592", 
                "Noxafil\u00ae"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Posaconazole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Orange", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92868"
                    }, 
                    "name": "Call for Information (Investigational Site 0007)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20010"
                    }, 
                    "name": "Call for Information (Investigational Site 0003)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gainesville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32610"
                    }, 
                    "name": "Call for Information (Investigational Site 0046)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21231"
                    }, 
                    "name": "Call for Information (Investigational Site 0021)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Call for Information (Investigational Site 0038)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Hyde Park", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11040"
                    }, 
                    "name": "Call for Information (Investigational Site 0004)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Call for Information (Investigational Site 0034)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toledo", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43606"
                    }, 
                    "name": "Call for Information (Investigational Site 0033)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Call for Information (Investigational Site 0037)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98105"
                    }, 
                    "name": "Call for Information (Investigational Site 0045)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Medical Information Centre / Centre de l'information medicale de Merck Canada", 
                    "phone": "514-428-8600 / 1-800-567-2594"
                }, 
                "facility": {
                    "address": {
                        "city": "Kirkland", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H9H 3L1"
                    }, 
                    "name": "Merck Canada"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "German Medical Information Center", 
                    "phone": "49 800 673 673 673"
                }, 
                "facility": {
                    "address": {
                        "city": "Haar", 
                        "country": "Germany"
                    }, 
                    "name": "Merck Sharp & Dohme GmbH"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Platon Peristaris", 
                    "phone": "30 2109897322"
                }, 
                "facility": {
                    "address": {
                        "city": "Alimos", 
                        "country": "Greece"
                    }, 
                    "name": "Vianex, S.A. / MSD"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Caroline Doornebos", 
                    "phone": "31 23 515 3362"
                }, 
                "facility": {
                    "address": {
                        "city": "Haarlem", 
                        "country": "Netherlands"
                    }, 
                    "name": "Merck Sharp & Dohme BV"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Germany", 
                "Greece", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia (P03579)", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Average Plasma Concentration (Cavg) of Posaconazole After Single Dose and at Steady State", 
            "safety_issue": "No", 
            "time_frame": "Day 1 and Day 7"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01716234"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of Participants Experiencing an Adverse Event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 58 days"
            }, 
            {
                "measure": "Number of Participants Discontinuing Study Treatment Due to an AE", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2008", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}